

=====

Sequence Listing was accepted with existing errors.

See attached Validation Report.

If you need help call the Patent Electronic Business Center at (866) 217-9197 (toll free).

Reviewer: Anne Corrigan

Timestamp: Thu Jul 26 16:44:24 EDT 2007

=====

Application No: 10539828 Version No: 1.1

Input Set:

Output Set:

Started: 2007-07-26 16:44:12.142
Finished: 2007-07-26 16:44:12.307
Elapsed: 0 hr(s) 0 min(s) 0 sec(s) 165 ms
Total Warnings: 1
Total Errors: 1
No. of SeqIDs Defined: 5
Actual SeqID Count: 5

Error code	Error Description
E 287	Invalid WIPO ST.2 date format; Use (YYYY-MM-DD) in <151>
W 213	Artificial or Unknown found in <213> in SEQ ID (5)

SEQUENCE LISTING

<110> INNATE PHARMA

<120> Pharmaceutical Compositions Having an Effect on the
Proliferation of NK Cells and a Method Using the Same

<130> B0207WO

<140> 10539828

<141> 2007-07-09

<150> US 60/435,344

<151> 23/12/2003

<160> 5

<170> PatentIn Ver. 2.1

<210> 1

<211> 190

<212> PRT

<213> Homo sapiens

<400> 1

Met Ala Trp Met Leu Leu Leu Ile Leu Ile Met Val His Pro Gly Ser
1 5 10 15

Cys Ala Leu Trp Val Ser Gln Pro Pro Glu Ile Arg Thr Leu Glu Gly
20 25 30

Ser Ser Ala Phe Leu Pro Cys Ser Phe Asn Ala Ser Gln Gly Arg Leu
35 40 45

Ala Ile Gly Ser Val Thr Trp Phe Arg Asp Glu Val Val Pro Gly Lys
50 55 60

Glu Val Arg Asn Gly Thr Pro Glu Phe Arg Gly Arg Leu Ala Pro Leu
65 70 75 80

Ala Ser Ser Arg Phe Leu His Asp His Gln Ala Glu Leu His Ile Arg
85 90 95

Asp Val Arg Gly His Asp Ala Ser Ile Tyr Val Cys Arg Val Glu Val
100 105 110

Leu Gly Leu Gly Val Gly Thr Gly Asn Gly Thr Arg Leu Val Val Glu
115 120 125

Lys Glu His Pro Gln Leu Gly Ala Gly Thr Val Leu Leu Leu Arg Ala
130 135 140

Gly Phe Tyr Ala Val Ser Phe Leu Ser Val Ala Val Gly Ser Thr Val
145 150 155 160

Tyr Tyr Gln Gly Lys Cys His Cys His Met Gly Thr His Cys His Ser
165 170 175

Ser Asp Gly Pro Arg Gly Val Ile Pro Glu Pro Arg Cys Pro
180 185 190

<210> 2
<211> 120
<212> PRT
<213> Homo sapiens

<400> 2
Leu Trp Val Ser Gln Pro Pro Glu Ile Arg Thr Leu Glu Gly Ser Ser
1 5 10 15

Ala Phe Leu Pro Cys Ser Phe Asn Ala Ser Gln Gly Arg Leu Ala Ile
20 25 30

Gly Ser Val Thr Trp Phe Arg Asp Glu Val Val Pro Gly Lys Glu Val
35 40 45

Arg Asn Gly Thr Pro Glu Phe Arg Gly Arg Leu Ala Pro Leu Ala Ser
50 55 60

Ser Arg Phe Leu His Asp His Gln Ala Glu Leu His Ile Arg Asp Val
65 70 75 80

Arg Gly His Asp Ala Ser Ile Tyr Val Cys Arg Val Glu Val Leu Gly
85 90 95

Leu Gly Val Gly Thr Gly Asn Gly Thr Arg Leu Val Val Glu Lys Glu
100 105 110

His Pro Gln Leu Gly Ala Gly Thr
115 120

<210> 3
<211> 19
<212> PRT
<213> Homo sapiens

<400> 3
Val Leu Leu Leu Arg Ala Gly Phe Tyr Ala Val Ser Phe Leu Ser Val
1 5 10 15

Ala Val Gly

<210> 4
<211> 33
<212> PRT
<213> Homo sapiens

<400> 4
Ser Thr Val Tyr Tyr Gln Gly Lys Cys His Cys His Met Gly Thr His
1 5 10 15

Cys His Ser Ser Asp Gly Pro Arg Gly Val Ile Pro Glu Pro Arg Cys
20 25 30

Pro

<210> 5
<211> 15
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: peptide derived
from natural sequence, useful for antiserum
production

<400> 5
Trp Val Ser Gln Pro Pro Glu Ile Arg Thr Leu Glu Gly Ser Cys
1 5 10 15